Journal of Clinical Epidemiology
Volume 49, Issue 12 , Pages 1453-1457 , December 1996

Recent trends in the consumption of lipid-lowering drugs in Finland

  • Jaana Martikainen

      Affiliations

    • Corresponding Author InformationAddress for correspondence to: Jaana Martikainen, Lic. Pharm., Research and Development Unit, The Social Insurance Institution, P.O. Box 450, Fin-00101 Helsinki, Finland.
    • Research and Development Unit, The Social Insurance Institution Helsinki, Finland
    • ,
  • Timo Klaukka

      Affiliations

    • Research and Development Unit, The Social Insurance Institution Helsinki, Finland
    • ,
  • Antti Reunanen

      Affiliations

    • Research and Development Unit, The Social Insurance Institution Helsinki, Finland
    • National Public Health Institute Helsinki, Finland
    • ,
  • Sirpa Peura

      Affiliations

    • Research and Development Unit, The Social Insurance Institution Helsinki, Finland
    • ,
  • Hannes Wahlroos

      Affiliations

    • National Agency for Medicines, Helsinki, Finland

,Accepted 5 June 1996.

References 

  1. Nordic Council on Medicines . Nordic Statistics on Medicines 1987–1989. Uppsala: NLN Publication No 30. 1990;
  2. Nordic Council on Medicines . Nordic Statistics on Medicines 1990–1992. Uppsala: NLN Publication No 34. 1993;
  3. Henry DA, Cully LR, Grigson T, Lee C. Recent trends in the prescribing of cholesterol lowering drugs in Australia. Med J Aust. 1991;155:332–336
  4. Klose G, Schwabe U. Lipidsenkende Mittel. In: 6th ed..  Schwabe U,  Paffrath D editor. Arzneiverordnungs-Report '91. Stuttgart and Jena: Gustav Fischer Verlag; 1991;p. 273–278
  5. Use of cholesterol-lowering drugs. United States, 1992. Stat Bull Metrop Insur Co. 1993;74(4):10–17
  6. Gozlan M. European drug consumption. Lancet. 1994;344:1695–1696
  7. Boumendil EF. Descriptive study of lipid-modulating drug use in a French professional population. J Clin Epidemiol. 1994;47:1163–1171
  8. WHO MONICA Project . WHO MONICA Project: Risk factors. Int J Epidemiol. 1989;18(Suppl 1):S46–S55
  9. Nordenstam I, Wennberg M, Kristoferson K. In: 6th ed.. Svensk läkemedelsstatistik 1993. (Swedish drug statistics 93), Stockholm: Apoteksbolaget; 1994;
  10. Garber AM, Littenberg B, Sox HC, Wagner JL, Gluck M. Costs and health consequences of cholesterol screening for asymptomatic older Americans. Arch Intern Med. 1991;151:1089–1095
  11. LaRosa JC. Dyslipoproteinemia in women and the elderly. Med Clin N Amer. 1994;78:163–180
  12. Martikainen J, Reunanen A, Klaukka T, Viikari L, Viikari J. Vain pieni osa aloitetusta lipidilääkityksestä keskeytyy. (Only a small proportion of patients with lipid lowering drug therapy discontinues the medication, in Finnish). Suomen Lääkärilehti. (Finnish Medical Journal), 1995;50:2090–2095
  13. Viikari J, Tikkanen M, Härkönen M, Jokinen A, Jägerholm S, Jäättelä A, et al.  Miten hyperkolesterolemiapotilaat pysyvät lääkehoidossa? (Do patients with hypercholesterolemia continue their drug therapy? In Finnish). Suomen Lääkärilehti. (Finnish Medical Journal), 1993;48:411–412
  14. Goldstein JL, Brown MS. Familial hypercholesterolemia. In:  Scriver CR,  Beaudet AL,  Sly WS,  Valle D editor. The Metabolic Basis of Inherited Diseases. 6th ed.. New York: McGraw Hill Book Inc; 1989;p. 1215–1249
  15. Slack J. Inheritence of familial hypercholesterolemia. Atherosclerosis Rev. 1979;5:35–65
  16. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544–1568
  17. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study. Ann Intern Med. 1971;74:1–12
  18. Andersen GE, Lous P, Friis-Hansen B. Screening for hyperlipoproteinemia in 10,000 Danish newborns. Follow-up studies in 522 children with elevated cord serum VLDL-LDL-cholesterol. Acta Paediatr Scand. 1979;68:541–545
  19. Criqui MH. Cholesterol, primary and secondary prevention, and allcause mortality. Ann Intern Med. 1991;115:973–976
  20. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs?. Br Med J. 1992;304:431–434
  21. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  22. Academy of Finland, Medical Research Council . In: Consensus development conference statement: Blood cholesterol and coronary heart disease. Ann Med. 21:1989;p. 415–424
  23. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300–1331

PII: S0895-4356(96)00267-3

Journal of Clinical Epidemiology
Volume 49, Issue 12 , Pages 1453-1457 , December 1996

Article Tools